American Journal of Kidney Diseases
Volume 45, Issue 1 , Pages 119-126 , January 2005

HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients

Presented as an abstract at the 2001 ASN/ISN World Congress of Nephrology, San Francisco, CA, October 2001.

  • Nancy A. Mason, PharmD

      Affiliations

    • College of Pharmacy, University of Michigan, Ann Arbor, MI USA.
    • Nephrology Pharmacy Associates, Ann Arbor, MI USA.
    • Corresponding Author InformationAddress reprint requests to Nancy A. Mason, PharmD, University of Michigan College of Pharmacy, 428 Church St, Ann Arbor, MI 48109-1065.
    • ,
  • George R. Bailie, PharmD, PhD

      Affiliations

    • Nephrology Pharmacy Associates, Ann Arbor, MI USA.
    • Renal Research Institute Inc, New York, NY USA.
    • Albany College of Pharmacy, Albany, NY.
    • ,
  • Sudtida Satayathum, MS

      Affiliations

    • University Renal Research and Education Association, Ann Arbor, MI.
    • ,
  • Jennifer L. Bragg-Gresham, MS

      Affiliations

    • University Renal Research and Education Association, Ann Arbor, MI.
    • ,
  • Takashi Akiba, MD, PhD

      Affiliations

    • Tokyo Women’s Medical University, Tokyo, Japan.
    • ,
  • Tadao Akizawa, MD, PhD

      Affiliations

    • Wakayama Medical University, Wakayama, Japan.
    • ,
  • Christian Combe, MD

      Affiliations

    • Hôpital St André, Bordeaux, France.
    • ,
  • Hugh C. Rayner, MD

      Affiliations

    • Birmingham Heartlands Hospital, Birmingham, UK.
    • ,
  • Akira Saito, MD

      Affiliations

    • Tokai University, Kanagawa, Japan.
    • ,
  • Brenda W. Gillespie, PhD

      Affiliations

    • Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI USA.
    • ,
  • Eric W. Young, MD

      Affiliations

    • Division of Nephrology, Department of Veterans Affairs Medical Center, University of Michigan Ann Arbor, MI USA.

Received 5 April 2004 ,Accepted 1 September 2004.

References 

  1. US Renal Data System . USRDS 2002 Annual Data Report . Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2002;
  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . JAMA . 2001;285:2486–2497
  3. Locatelli F , Bommer J , London GM , et al.   Cardiovascular disease determinants in chronic renal failure (Clinical approach and treatment) . Nephrol Dial Transplant . 2001;16:459–468
  4. Wanner C , Krane V , Metzger T , Quaschning T . Lipid changes and statins in chronic renal insufficiency and dialysis . J Nephrol . 2001;14(suppl 4):S76–S80
  5. National Kidney Foundation . K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease . Am J Kidney Dis . 2003;41(suppl 3):S1–S92
  6. Young EW , Goodkin DA , Mapes DL , et al.   The Dialysis Outcomes and Practice Patterns Study (DOPPS) (An international hemodialysis study) . Kidney Int Suppl . 2000;74:S74–S81
  7. Goodkin DA , Mapes DL , Held PJ . The Dialysis Outcomes and Practice Patterns Study (DOPPS) (How can we improve the care of hemodialysis patients?) . Semin Dial . 2001;14:157–159
  8. Klein JP , Moeschberger ML . Survival Analysis Techniques for Censored and Truncated Data . New York, NY: Springer; 1997; 417
  9. Seliger SL , Weiss NS , Gillen DL , et al.   HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients . Kidney Int . 2002;61:297–304
  10. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (The Scandinavian Simvastatin Survival Study (4S)) . Lancet . 1994;344:1383–1389
  11. Sacks FM , Pfeffer MA , Moye LA , et al.   The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels . N Engl J Med . 1996;335:1001–1009
  12. Shepherd J , Cobbe SM , Ford I , et al.   Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia . N Engl J Med . 1995;333:1301–1307
  13. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals (A randomised placebo-controlled trial) . Lancet . 2002;360:7–22
  14. Tonelli M , Sacks FM , Kiberd B , et al.   Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency . Ann Intern Med . 2003;138:98–104
  15. Sever PS , Dahløf B , Poulter NR , et al.   Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) (A multicentre randomised controlled trial) . Lancet . 2003;361:1149–1158
  16. Holdaas H , Fellström B , Jardine AG , et al.   Effect of fluvastatin on cardiac outcomes in renal transplant recipients (A multicentre, randomized, placebo controlled trial) . Lancet . 2003;361:2024–2031
  17. Liu Y , Coresh J , Eustace JA , et al.   Association between cholesterol level and mortality in dialysis patients . JAMA . 2004;291:451–459
  18. Seliger SL , Stehman-Breen CO . Are HMG-CoA reductase inhibitors underutilized in dialysis patients? . Semin Dial . 2003;16:179–185
  19. Longenecker JC , Coresh J , Powe NR , et al.   Traditional cardiovascular disease risk factors in dialysis patients compared with the general population (The CHOICE study) . J Am Soc Nephrol . 2002;13:1918–1927
  20. Harris K , Thomas M , Short C , Moore R . Assessment of the efficiency of treatment of dyslipidaemia in renal outpatients . J Nephrol . 2002;15:263–269
  21. Saltissi D , Morgan C , Rigby RJ , Westhuyzen J . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis . Am J Kidney Dis . 2002;39:283–290
  22. Chang JW , Yang WS , Min WK , et al.   Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients . Am J Kidney Dis . 2002;39:1213–1217
  23. Harris KP , Wheeler DC , Chong CC  Atorvastatin in CAPD Study Investigators . A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD . Kidney Int . 2002;61:1469–1474
  24. Fellstrom B , Holdaas H , Jardine A . Why do we need a statin trial in hemodialysis patients? . Kidney Int Suppl . 2003;84:S204–S206
  25. Baigent C , Landry M . Study of Heart and Renal Protection (SHARP) . Kidney Int Suppl . 2003;84:S207–S210
  26. Wanner C , Krane V , Ruf G , et al.  Die Deutsche Diabetes Dialyse Studie Investigators   Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis . Kidney Int . 1999;71(Suppl):S222–S226

 The Dialysis Outcomes and Practice Patterns Study is supported by research grants from Amgen Inc and Kirin Brewery Ltd without restrictions on publications. This project was funded in part by Renal Research Institute Inc.

PII: S0272-6386(04)01412-X

doi: 10.1053/j.ajkd.2004.09.025

American Journal of Kidney Diseases
Volume 45, Issue 1 , Pages 119-126 , January 2005

Article Tools

* Image Usage & Resolution